Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Fosforilados > Hematology > Flashcards

Hematology Flashcards

1
Q

Lab test to help distinguish coagulopathy of liver disease from DIC

A

Factor VIII level

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hemoglobin transfusion threshold for most patients

A

<7 g/dL

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Medication and dosing frequency for iron therapy

A

Once-daily or alternate-day ferrous sulfate

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MDS gold standard diagnostic test

A

Bone marrow biopsy

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Indications for a transfusion threshold >7 g/dL

A

ACS, acute stroke, hemodynamic instability, active bleeding

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Treatment of CKD-related anemia

A

Erythropoietin

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Optimal evaluation of lytic bone lesions in MM

A

MRI or PET

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Erythrocyte index correlating with uniformity or variability in erythrocyte size

A

RDW

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Decision support tool for suspected TTP management while ADAMTS13 level pending

A

PLASMIC score

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Management of anemia of inflammation

A

Treat underlying cause

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Transfusion therapy for ACS and ARDS in SCD

A

Exchange transfusion

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Microcytosis, normal RDW, normal or increased erythrocyte count

A

Thalassemia

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dabigatran reversal agent

A

Idarucizumab

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Initial decision support tool in evaluating low-risk PE

A

PERC

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment of SCD with frequent pain events, severe symptomatic anemia, previous ACS, or stroke

A

Hydroxyurea

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Curative treatment for myelofibrosis

A

Allogeneic HSCT

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Unprovoked VTE treatment duration

A

> 6 months

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Vitamin K deficiency–related coagulation profile

A

Elevated PT, normal or mildly elevated aPTT

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hemochromatosis screening tests

A

Transferrin saturation, serum ferritin

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Agglutinated erythrocytes, DAT showing C3

A

Cold agglutinin disease

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Hemolytic anemia, bite cells, Heinz bodies

A

G6PD deficiency

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Initial treatment of chronic-phase CML

A

TKI

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Cold agglutinin disease treatment

A

Rituximab

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Most common cause of classic HUS

A

Shiga toxin–producing E. coli

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Outpatient therapy for acute low-risk PE

A

Apixaban, rivaroxaban

MKSAP 20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Pancytopenia, severe bone marrow hypocellularity

A

Aplastic anemia

MKSAP 20

Aplastic anemia is characterized by the failure of the bone marrow to produce sufficient blood cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Autoimmune gastritis and intrinsic factor deficiency causing vitamin B12 deficiency

A

Pernicious anemia

MKSAP 20

Pernicious anemia is an autoimmune condition that affects the absorption of vitamin B12.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Management of porphyria cutanea tarda

A

Phlebotomy

MKSAP 20

Phlebotomy is often used to reduce iron overload in patients with porphyria cutanea tarda.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Anticoagulation for distal DVT without symptoms or risk factors for extension

A

None

MKSAP 20

In cases of distal DVT without symptoms or risk factors, anticoagulation may not be necessary.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Duration of smoking-induced neutrophilia following smoking cessation

A

≥1 year

MKSAP 20

Neutrophil levels may remain elevated for at least one year after quitting smoking.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Oral therapy for HIT

A

DOAC (e.g., rivaroxaban)

MKSAP 20

Direct oral anticoagulants (DOACs) like rivaroxaban are used for treating heparin-induced thrombocytopenia (HIT).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Management of warfarin over-anticoagulation, INR >10, no bleeding

A

Stop warfarin, give oral vitamin K

MKSAP 20

This is the recommended approach for managing significant over-anticoagulation without bleeding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Evaluation of PE in patients with contraindication to IV contrast

A

V/Q scan

MKSAP 20

A ventilation-perfusion (V/Q) scan is used to evaluate pulmonary embolism when IV contrast cannot be administered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Symptomatic hyperviscosity treatment

A

Therapeutic apheresis

MKSAP 20

Therapeutic apheresis is used to reduce blood viscosity in symptomatic patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Duration of VTE prophylaxis in pregnant person with SCD

A

While hospitalized and 6 weeks postpartum

MKSAP 20

VTE prophylaxis is crucial for pregnant individuals with sickle cell disease during and after hospitalization.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Transfusion for warm autoimmune hemolytic anemia without crossmatch compatible blood

A

ABO- and Rh-matched transfusion

MKSAP 20

In cases of warm autoimmune hemolytic anemia, it is important to use ABO- and Rh-matched blood for transfusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Two main causes of kidney disease in MM

A

Hypercalcemia and cast nephropathy

MKSAP 20

Multiple myeloma can lead to kidney disease primarily due to hypercalcemia and cast nephropathy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

HIT therapy duration with documented thromboembolic event

A

At least 3 months

MKSAP 20

Patients with HIT and a thromboembolic event require at least three months of therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Noncardiogenic pulmonary edema 6 hours after transfusion

A

TRALI

MKSAP 20

Transfusion-related acute lung injury (TRALI) can occur shortly after blood transfusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Preoperative management of patient with SCD for surgery requiring general anesthesia

A

Simple transfusion with target hemoglobin 10 g/dL

MKSAP 20

This approach helps reduce the risk of complications during surgery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Confirms folate deficiency when serum folate level is normal

A

Elevated serum homocysteine level

MKSAP 20

Elevated homocysteine can indicate folate deficiency even when serum folate is within normal limits.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Treatment of DIC-related hypofibrinogenemia

A

Cryoprecipitate

MKSAP 20

Cryoprecipitate is used to manage low fibrinogen levels in disseminated intravascular coagulation (DIC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

MM preferred treatment

A

Autologous HSCT

MKSAP 20

Autologous hematopoietic stem cell transplantation is a preferred treatment for multiple myeloma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Risk factors for upper extremity DVT

A

Central venous catheter, malignancy

MKSAP 20

These factors significantly increase the risk of developing upper extremity deep vein thrombosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

IgM paraprotein, hyperviscosity

A

Waldenström macroglobulinemia

MKSAP 20

Waldenström macroglobulinemia is characterized by elevated IgM levels leading to hyperviscosity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Safe ITP platelet count during pregnancy

A

> 30,000/µL (30 × 10^9/L)

MKSAP 20

A platelet count above this threshold is considered safe in pregnant patients with immune thrombocytopenic purpura (ITP).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Treatment of pre-eclampsia–related thrombocytopenia

A

Delivery

MKSAP 20

The definitive treatment for thrombocytopenia related to pre-eclampsia is delivery of the baby.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Increased infection risk in hereditary hemochromatosis

A

Vibrio vulnificus and Yersinia enterocolitica

MKSAP 20

Individuals with hereditary hemochromatosis are at increased risk for infections from these organisms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Fever, tachypnea, hypoxia, cough, dyspnea, pulmonary infiltrates in patients with SCD

A

ACS

MKSAP 20

Acute chest syndrome (ACS) is a serious complication in sickle cell disease characterized by these symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Isolated mild asymptomatic neutropenia in a patient of African descent

A

Duffy-null associated neutrophil count

MKSAP 20

This condition can be a benign variant seen in some individuals of African descent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Confirms vitamin B12 deficiency when cobalamin level is borderline

A

Elevated serum methylmalonic acid level

MKSAP 20

Methylmalonic acid (MMA) is a marker that helps in the diagnosis of vitamin B12 deficiency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Treatment to shorten recovery time in drug-induced neutropenia with active infection

A

G-CSF

MKSAP 20

G-CSF stands for granulocyte colony-stimulating factor, which stimulates the production of white blood cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Treatment of MM-related hypogammaglobulinemia and recurrent infections

A

IVIG

MKSAP 20

IVIG stands for intravenous immunoglobulin, which provides antibodies to help fight infections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Microcytic anemia, increased hemoglobin A2 and F

A

β-Thalassemia minor

MKSAP 20

β-Thalassemia minor is a genetic blood disorder that affects hemoglobin production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Prolonged aPTT, low factor VIII, no correction with mixing study

A

Acquired hemophilia

MKSAP 20

Acquired hemophilia is often associated with autoimmune disorders and can lead to significant bleeding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

MGUS with unexplained kidney disease

A

Monoclonal gammopathy of renal significance

MKSAP 20

MGUS stands for monoclonal gammopathy of undetermined significance, which can lead to renal complications.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Mucocutaneous bleeding, normal platelet count and coagulation tests

A

Qualitative platelet disorder

MKSAP 20

This condition indicates a dysfunction in platelet function rather than quantity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

DOAC for patients receiving dialysis

A

Apixaban

MKSAP 20

Direct oral anticoagulants (DOACs) like apixaban are often preferred for their safety profile in renal impairment.

59
Q

Macrocytic anemia, malnutrition, alcohol use disorder

A

Folate deficiency

MKSAP 20

Folate deficiency is a common cause of macrocytic anemia and can be exacerbated by alcohol use.

60
Q

Post-DVT pain, edema, stasis dermatitis

A

Postthrombotic syndrome

MKSAP 20

Postthrombotic syndrome can occur after deep vein thrombosis and lead to chronic pain and swelling.

61
Q

Hemolytic anemia, spherocytes, positive DAT

A

Warm autoimmune hemolytic anemia

MKSAP 20

Warm autoimmune hemolytic anemia is characterized by spherocytes in the blood and a positive direct antiglobulin test (DAT).

62
Q

Most common indications for autologous HSCT

A

Multiple myeloma, relapsed aggressive lymphoma

MKSAP 20

Autologous hematopoietic stem cell transplantation (HSCT) is often used in these hematologic malignancies.

63
Q

Lab test to diagnose PNH

A

Flow cytometry (demonstrates loss of CD55 and CD59)

MKSAP 20

PNH stands for paroxysmal nocturnal hemoglobinuria, and flow cytometry helps identify affected cells.

64
Q

Concomitant anticoagulant duration with warfarin for acute VTE

A

At least 5 days and therapeutic INR at least 24 hours

MKSAP 20

Venous thromboembolism (VTE) treatment often requires bridging with anticoagulants before achieving therapeutic INR.

65
Q

Erythrocytosis, positive JAK2

A

Polycythemia vera

MKSAP 20

Polycythemia vera is a myeloproliferative disorder characterized by increased red blood cell mass.

66
Q

SCD-related pulmonary vascular complication of pregnancy

A

Pulmonary hypertension

MKSAP 20

Sickle cell disease (SCD) can lead to various complications, including pulmonary hypertension, especially during pregnancy.

67
Q

Aminotransferase elevation, arthritis of the 2nd and 3rd metacarpophalangeal joints

A

Hereditary hemochromatosis

MKSAP 20

Hereditary hemochromatosis can cause liver damage and joint issues due to iron overload.

68
Q

Mild, asymptomatic thrombocytopenia late in pregnancy

A

Gestational thrombocytopenia

MKSAP 20

Gestational thrombocytopenia is common and usually resolves after delivery.

69
Q

Therapy for primary HES with PDGFR-α or -β variant

A

Imatinib

MKSAP 20

Imatinib is a targeted therapy used for certain hematologic malignancies and conditions like hypereosinophilia syndrome (HES).

70
Q

Lab finding of citrate toxicity during massive transfusion

A

Hypocalcemia

MKSAP 20

Citrate, used as an anticoagulant in blood products, can bind calcium, leading to hypocalcemia.

71
Q

Less invasive tissue biopsy site for systemic amyloidosis

A

Abdominal fat pad

MKSAP 20

An abdominal fat pad biopsy is a common and effective method for diagnosing systemic amyloidosis.

72
Q

Prophylactic therapy for hemophilia A

A

Emicizumab

MKSAP 20

Emicizumab is a bispecific monoclonal antibody that mimics the function of factor VIII in hemophilia A patients.

73
Q

PV therapy for patients intolerant of first-line agents

A

Ruxolitinib

MKSAP 20

Ruxolitinib is a JAK1/JAK2 inhibitor used in polycythemia vera for patients who cannot tolerate conventional therapies.

74
Q

Genetic testing for abdominal thrombosis, splenomegaly, portal hypertension

A

JAK2

MKSAP 20

JAK2 mutations are commonly associated with myeloproliferative neoplasms, including conditions leading to thrombosis.

75
Q

Testing indicated for moderate- to high-probability Wells score for DVT and PE

A

Duplex imaging for DVT; CT angiography for PE

MKSAP 20

The Wells score helps stratify the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), guiding diagnostic imaging.

76
Q

Inherited cause of mucosal bleeding; normal PT, aPTT, and platelets

A

vWD

MKSAP 20

von Willebrand Disease (vWD) is characterized by a deficiency in von Willebrand factor, which is crucial for platelet adhesion.

77
Q

Cancer screening with unprovoked VTE

A

Age- and sex-appropriate screening

MKSAP 20

Unprovoked venous thromboembolism (VTE) may indicate an underlying malignancy that requires thorough screening.

78
Q

Monoclonal protein <3 g/dL, clonal plasma cells <10% of marrow cellularity, no end-organ damage

A

MGUS

MKSAP 20

Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition to multiple myeloma.

79
Q

Additional testing in most patients with thrombocytopenia and low 4T score

A

None

MKSAP 20

The 4T score helps assess the probability of heparin-induced thrombocytopenia (HIT).

80
Q

Treatment of asymptomatic ET in older patients

A

Hydroxyurea and low-dose aspirin

MKSAP 20

Essential thrombocythemia (ET) management aims to reduce thrombotic risk.

81
Q

AL amyloidosis preferred treatment

A

Autologous HSCT

MKSAP 20

Autologous hematopoietic stem cell transplantation (HSCT) is the preferred treatment for eligible patients.

82
Q

Ineffective hematopoiesis, hypercellular marrow, peripheral cytopenia, normal vitamin B12 and folate

A

MDS

MKSAP 20

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis leading to cytopenias.

83
Q

PCD with monoclonal protein exceeding limit for MGUS, no other symptoms, no end-organ damage

A

Smoldering MM

MKSAP 20

Smoldering multiple myeloma (MM) indicates a higher risk of progression compared to MGUS.

84
Q

Emergent reversal of unfractionated heparin

A

Protamine sulfate

MKSAP 20

Protamine sulfate is used to neutralize the anticoagulant effects of heparin.

85
Q

Effect of known inherited thrombophilia on acute VTE management

A

None

MKSAP 20

Known inherited thrombophilias do not alter the immediate management of acute venous thromboembolism.

86
Q

Optimal therapy for severe aplastic anemia in younger patients

A

Allogeneic HSCT

MKSAP 20

Allogeneic hematopoietic stem cell transplantation (HSCT) is preferred for younger patients due to better outcomes.

87
Q

Management of hemophilia A, minor bleeding

A

Desmopressin

MKSAP 20

Desmopressin is used to increase factor VIII levels in patients with hemophilia A.

88
Q

Eosinophilia and end-organ damage

A

HES

MKSAP 20

Hypereosinophilic syndrome (HES) is characterized by eosinophilia and damage to various organs.

89
Q

Management of life-threatening bleeding in patients taking oral Xa inhibitors

A

Four-factor PCC or andexanet alfa

MKSAP 20

Prothrombin complex concentrate (PCC) and andexanet alfa are used for reversal of anticoagulation.

90
Q

Initial evaluation of suspected platelet dysfunction

A

Platelet function analyzer

MKSAP 20

Platelet function analyzers assess the functional capacity of platelets.

91
Q

Posttransfusion dyspnea, elevated CVP, elevated BNP

A

TACO

MKSAP 20

Transfusion-associated circulatory overload (TACO) can occur after blood transfusions, leading to respiratory distress.

92
Q

Management of ITP with severe thrombocytopenia and bleeding

A

Glucocorticoids with or without IVIG

MKSAP 20

Immune thrombocytopenic purpura (ITP) treatment may include glucocorticoids and intravenous immunoglobulin (IVIG) for severe cases.

93
Q

Normochromic, normocytic anemia; elevated ferritin; low iron and TIBC

A

Anemia of inflammation

MKSAP 20

Anemia of inflammation occurs due to chronic disease and is characterized by normal iron stores but impaired utilization.

94
Q

Target hemoglobin level for ESA treatment in ESKD

A

10-11 g/dL

MKSAP 20

Erythropoiesis-stimulating agents (ESAs) are used to manage anemia in end-stage kidney disease (ESKD).

95
Q

Management of type I HIT

A

No further testing or therapy

MKSAP 20

Type I HIT is generally mild and resolves without intervention.

96
Q

TTP treatment

A

Plasma exchange, glucocorticoids, rituximab

MKSAP 20

Thrombotic thrombocytopenic purpura (TTP) requires urgent treatment to prevent complications.

97
Q

Treatment of complement-mediated HUS

A

Eculizumab

MKSAP 20

Eculizumab is a complement inhibitor used in atypical hemolytic uremic syndrome (HUS).

98
Q

Iron overload, cutaneous blisters, hypertrichosis

A

Porphyria cutanea tarda

MKSAP 20

Porphyria cutanea tarda is associated with hepatic iron overload and skin manifestations.

99
Q

Thrombocytopenia, prolonged aPTT and PT, elevated INR, hypofibrinogenemia, and elevated D-dimer level

A

DIC

MKSAP 20

Disseminated intravascular coagulation (DIC) is a complex disorder often secondary to severe conditions.

100
Q

Most common cause of iron deficiency in men and postmenopausal women

A

GI blood loss

MKSAP 20

Gastrointestinal bleeding is the leading cause of iron deficiency anemia in these populations.

101
Q

Treatment of acute proximal DVT or PE when anticoagulation is contraindicated

A

Retrievable or temporary IVC filter

MKSAP 20

IVC stands for inferior vena cava, and filters are used to prevent blood clots from reaching the lungs.

102
Q

VTE prevention in high-risk APLAS

A

Warfarin

MKSAP 20

APLAS refers to antiphospholipid syndrome, a condition that increases the risk of blood clots.

103
Q

Management of hemophilia A, active bleeding, high titer inhibitor

A

Activated factor VII

MKSAP 20

This treatment is used because traditional factor VIII replacement is ineffective in the presence of inhibitors.

104
Q

Skin, GI, and liver injury following allogeneic HSCT

A

Graft-versus-host disease

MKSAP 20

Allogeneic HSCT refers to allogeneic hematopoietic stem cell transplantation, where donor cells attack the recipient’s tissues.

105
Q

Management of asymptomatic ITP and platelet count 35,000/μL (30 × 10^9/L)

A

Observation

MKSAP 20

ITP stands for immune thrombocytopenic purpura, a condition characterized by low platelet counts.

106
Q

MDS therapy that reduces transfusion requirements and AML conversion risk

A

Hypomethylating agent (azacytidine or decitabine)

MKSAP 20

MDS refers to myelodysplastic syndromes, which can progress to acute myeloid leukemia (AML).

107
Q

Secondary iron overload treatment

A

Iron chelation

MKSAP 20

This treatment helps remove excess iron from the body, often necessary in patients with repeated blood transfusions.

108
Q

Episodic hemolysis, marrow aplasia, unusual site of thrombosis, erythrocytes lacking CD55 and CD59

A

PNH

MKSAP 20

PNH stands for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.

109
Q

Pancytopenia, promyelocytes, and DIC

A

Acute promyelocytic leukemia

MKSAP 20

DIC stands for disseminated intravascular coagulation, a serious condition associated with this type of leukemia.

110
Q

Common causes of vitamin K deficiency

A

Malnutrition, prolonged antibiotics

MKSAP 20

Vitamin K is crucial for blood clotting, and its deficiency can lead to bleeding problems.

111
Q

Treatment of factor VIII inhibitor–related bleeding

A

Activated factor VII, activated PCC, or recombinant porcine factor VIII

MKSAP 20

PCC stands for prothrombin complex concentrate, used in the management of bleeding in hemophilia.

112
Q

Monoclonal B lymphocytes, no other clinical features to suggest CLL

A

Monoclonal B-cell lymphocytosis

MKSAP 20

CLL stands for chronic lymphocytic leukemia, but this condition represents an early stage or benign form.

113
Q

Infectious cause of aplastic anemia

A

Parvovirus B19

MKSAP 20

This virus can suppress bone marrow function, leading to decreased blood cell production.

114
Q

Supplement to increase iron absorption

A

Vitamin C

MKSAP 20

Vitamin C enhances the absorption of non-heme iron from plant sources.

115
Q

Warfarin-related life-threatening bleeding treatment

A

Four-factor PCC

MKSAP 20

This treatment provides the necessary clotting factors to reverse the effects of warfarin.

116
Q

Management of liver disease, hypofibrinogenemia, active bleeding

A

Cryoprecipitate

MKSAP 20

Cryoprecipitate is rich in clotting factors, especially fibrinogen, which is crucial in bleeding scenarios.

117
Q

Deficiency causing heparin resistance and VTE

A

Antithrombin deficiency

MKSAP 20

Antithrombin is a protein that helps regulate blood clotting, and its deficiency can lead to thrombotic events.

118
Q

Malabsorption-related iron deficiency treatment

A

Parenteral iron

MKSAP 20

Parenteral iron is administered via injection or infusion, bypassing the gastrointestinal tract.

119
Q

Cause of pseudothrombocytopenia

A

Platelet clumping

MKSAP 20

This phenomenon can lead to falsely low platelet counts in laboratory tests.

120
Q

Microcytic anemia, normal hemoglobin electrophoresis, normal iron level

A

α-Thalassemia trait

MKSAP 20

This genetic condition affects the production of hemoglobin and is often asymptomatic.

121
Q

Mechanical causes of acquired vWD

A

Prosthetic heart valves, native valvular disease, LVAD

MKSAP 20

vWD stands for von Willebrand disease, which can be exacerbated by mechanical factors.

122
Q

Low hemoglobin level with indirect hyperbilirubinemia, elevated lactate dehydrogenase, low haptoglobin

A

Hemolytic anemia

MKSAP 20

These lab findings are indicative of increased destruction of red blood cells.

123
Q

Lab testing diagnostic of inherited hemophilia A or B

A

Prolonged aPTT (corrects with mixing study), normal PT and CBC

MKSAP 20

aPTT stands for activated partial thromboplastin time, a test used to assess blood coagulation.

124
Q

Treatment of massive PE with shock

A

Thrombolytic therapy

MKSAP 20

Thrombolytic therapy is used to dissolve blood clots quickly in emergency situations.

125
Q

Hemolysis, thrombocytopenia, ADAMTS13 deficiency

A

TTP

MKSAP 20

TTP stands for thrombotic thrombocytopenic purpura, a serious condition characterized by microangiopathic hemolytic anemia and thrombocytopenia.

126
Q

Acute promyelocytic leukemia treatment

A

All-trans retinoic acid

MKSAP 20

127
Q

Chronic hemolytic anemia, spherocytes, negative DAT

A

Hereditary spherocytosis

MKSAP 20

128
Q

Hypercalcemia, kidney failure, anemia, bone lesions, rouleaux formation

A

MM

MKSAP 20

129
Q

Common deficiency causing thrombocythemia

A

Iron

MKSAP 20

130
Q

Antibiotic management of HUS

A

Not indicated

MKSAP 20

131
Q

Infectious causes of ITP

A

HIV, hepatitis C virus, H. pylori

MKSAP 20

132
Q

Type 1 vWD treatment

A

Desmopressin

MKSAP 20

133
Q

Nephrotic syndrome, cardiomegaly, macroglossia

A

Systemic amyloidosis

MKSAP 20

134
Q

Confirmatory test for HIT when EIA is positive

A

Serotonin release or heparin-induced platelet aggregation assay

MKSAP 20

135
Q

Factor inhibitor evaluation in patients with prolonged aPTT

A

Mixing study

MKSAP 20

136
Q

5q− MDS treatment

A

Lenalidomide

MKSAP 20

137
Q

Predisposing condition for warfarin-related skin necrosis

A

Protein C deficiency

MKSAP 20

138
Q

Settings in which warfarin preferred to DOAC for acute VTE therapy

A

Prosthetic heart valve, high-risk APLAS

MKSAP 20

139
Q

Hematologic complication of testosterone supplementation

A

Erythrocytosis

MKSAP 20

140
Q

Lenalidomide unique toxicity

A

VTE

MKSAP 20

141
Q

Hereditary hemochromatosis treatment

A

Phlebotomy

MKSAP 20

142
Q

Adjunct to autologous HSCT and chemotherapy to prolong survival in MM

A

Bisphosphonate

MKSAP 20

143
Q

Treatment of superficial vein thrombosis with significant risk for progression

A

Low-dose fondaparinux

MKSAP 20

Fosforilados (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions